KR101241455B1 - Bean curd having hypotensive effect - Google Patents

Abstract

The present invention relates to a blood sugar-lowering tofu and a method of manufacturing the same, wherein the fermented extract containing fermented young barley sprouts and corn whiskers extract or young barley sprouts extract as an active ingredient is added together when the water is added to remove the ugly or astringent taste. Its purpose is to provide easy to ingest, lowering blood sugar and providing a high blood sugar lowering tofu and a method of preparing the same for treating insulin-independent diabetes.
Application of the present invention, the action of lowering blood sugar, preventing the rise of blood sugar and increasing the secretion of insulin, exhibits an excellent improvement effect on diabetes, the inherent shaggy and astringent taste of barley sprouts removed through fermentation By being easily eaten as food, it helps a lot of diabetic patients to control blood sugar and prevent diabetes, which has a lot of benefits in promoting national health for preventing adult diseases. In addition, since barley sprout is contained in tofu, the prepared tofu has a blue color, which is a unique color of barley sprout, which can induce curiosity of young children, but there are no side effects of artificial colors.

Description

Blood sugar lowering tofu and its manufacturing method {BEAN CURD HAVING HYPOTENSIVE EFFECT}

The present invention relates to a blood sugar-lowering tofu and a method for manufacturing the same, and more particularly, by adding together the young barley sprout extract and the corn beard extract or the young barley sprout extract as an active ingredient in the fermentation state, the fermentation is carried out together. The present invention relates to a tofu for lowering blood sugar and a method for producing the same, having a taste that is easily ingested and lowering blood sugar to have a high therapeutic effect on insulin-independent diabetes.

As is well known, diabetes mellitus and its complications are diseases with high mortality rates worldwide along with cancer and renal circulatory disease. Symptoms have been reported, diabetes patients have a high risk of complications such as eye disease, kidney disease, heart disease.

Symptoms of diabetes vary, but the three major symptoms are Daum, multi urine, Dasik. In other words, due to high blood sugar levels in the blood, glucose and large amounts of water are excreted by osmotic pressure, and the urine is frequently seen. Therefore, dehydration causes severe thirst to drink a lot of water. As a result, a lot of weight is reduced.

Diabetes is largely classified into insulin dependent diabetes mellitus (type 1) and insulin independent diabetes mellitus (type 2).

Insulin-dependent, type 1, can also cause serious symptoms, such as diabetic ketoacidosis. In the United States and Europe, about 5 to 10% of all diabetics are estimated to be insulin-dependent diabetes, type 1, but in Korea, about 1 to 2%.

It is associated with HLA antigens (HLA, DR, DQ), the genes that cause insulin type 1 diabetes mellitus. These autoimmune mechanisms have been shown to be involved in the development of diabetes mellitus and autoantibodies to islet cell insulin are produced. In recent years, efforts have been made to detect such autoantibodies before type 1 diabetes occurs to slow or prevent the onset of diabetes.

Insulin-dependent diabetes mellitus, type 2, develops mainly after the forties and accounts for most of the diabetic patients in Korea. Unlike type 1, it is called adult-type diabetes and its cause is not clear yet, but it is known to be caused by genetic factors and environmental factors involved.

Genetic factors include a variety of familial concentrations, with nearly 90-100% disease concordance between identical twins, 58% for children when both parents are diabetic, and 27% for parents when one of the parents is diabetic. It is known that about 0.9% of people are healthy. Environmental factors, such as high calorie intake, lack of exercise, obesity, stress and drug abuse, which are rapidly increasing with the recent economic growth, are causing the diabetes.

The pathogenesis of diabetes mellitus is observed in both pancreatic beta cells and in insulin secretion and in target insulins (insulin resistance). It is not yet clear what changes are of primary importance.

In the treatment of diabetes, hypoglycemic agents include sulfonylureas, biguanides, and acarbose. Among them, sulfonyl-urea preparations are second generation products with short duration of action and strong hypoglycemic effects. It is mainly used, and in patients with obese adult diabetes, biguanides and acarbose are used for diabetics with normal weight or more.

In addition, insulin used in the form of an injection is excellent in hypoglycemic effect, but not only inconvenient to use, but also low-glycemia complications need attention, especially in the elderly, such hypoglycemia well occurs, so it is necessary to be careful.

In addition to the drug therapy, there are a total of 158 folk remedies in Korea, and there are 153 folk remedies, and about 73% of adult diabetics have used folk remedies more than once.

The study of diabetes treatment drugs is focused on research and treatment fields. In the case of insulin-dependent cases, studies for preventing pancreatitis and treating diabetes are mainly conducted on disease model animals such as MOD mice and most diabetes treatment strategies. Focuses on suppressing and regulating immune responses to prevent beta cell destruction. Insulin-dependent diabetes mellitus (type 1 diabetes), an autoimmune disease, is due to augmented abnormal immune function and various immunotherapies have been attempted to prevent beta cell destruction of the pancreas.

Neonatal Thymectomy can eliminate T cells to suppress the development of diabetes in NOD mice. In addition, it has been found that treatment of antibodies to T cells removes T cells or macrophages to inhibit the onset of diabetes. It has been reported that the production and function of free radicals such as NO secreted from immune cells and anti-oxidants can be used to suppress diabetes, such as nicotinamide, vitamin E, probucol, etc. Antioxidants have been reported.

Therapies using immunosuppressants are being studied. However, the treatment of diabetes with glucocorticoid or cyclophosphamide has no significant effect. Recently, it has suggested the possibility of treating diabetes with cyclosporin A and rapamycin. The result is not yet clear.

Treatment with immunosuppressive agents causes secondary infections, kidney toxicity, liver toxicity due to excessive immune suppression, which still has many problems for use as a therapeutic agent for diabetes, and also causes cancer during long-term treatment. .

Recently, studies on the prevention and treatment of diabetes mellitus by immunomodulators other than immunosuppressants have been conducted, and it has been reported that the cytokines such as IL-4 and IL-10 inhibit the diabetes of NOD mice. In addition, efforts are being made to develop a therapeutic agent that can lower insulin side effects and treat insulin dependent and non-dependent diabetes at the same time.

Folk remedies have traditionally been known to have a variety of therapeutic effects with low toxicity. To date, the effects of diabetes treatment using dozens of herbal medicines have been reported, and there are reports that insulin-dependent and non-dependent diabetes can be treated simultaneously.

Ultimately, there are side effects, and when the side effects occur, it excludes drug treatments that can cause a very dangerous situation, such as hypoglycemia, and develops a functional food composition that is easy to ingest and fits well with other foods while having a high blood sugar lowering effect This is urgent.

In the case of tofu, soybean is used as a main substance, it supplies various nutrients to the ingestor and activates the physiological phenomenon of the ingestor. There was a problem that he was reluctant to eat tofu.

The present invention has been made in view of the above-described prior art, and the fermented extract containing the young barley sprouts and corn beard extracts or young barley sprouts as an active ingredient is added together when fermentation is added to remove the hot or astringent taste. Its purpose is to provide easy to ingest, lowering blood sugar and providing a high blood sugar lowering tofu and a method of preparing the same for treating insulin-independent diabetes.

In order to achieve the above object, according to a preferred embodiment of the present invention, 0.01 to 1% by weight of a coagulant is mixed with 100% by weight of soymilk obtained by pulverizing soybean, and 1 to 5 months old young barley sprout extract 1 to 5%. Provided is a tofu for lowering blood sugar, which is prepared by mixing and coagulating 5% by weight.

Preferably, the young barley sprout extract is an extract obtained by mixing 30 ml of rectified water per 100 g of barley sprout in a mixer, to provide a blood sugar lowering tofu.

Preferably, the young barley sprout extract is fermented to lower blood sugar, characterized in that the fermentation using Aspergillus oryzae and Aspergillus sojae (Aspergillus sojae).

Preferably, the young barley sprout extract is prepared by quenching the extract obtained by mixing 30 ml of rectified water per 100 g of barley sprout in a mixer, and placed in 0.1 wt% Aspergillus Oriza and 0.1 wt% Aspergillus element. A nutraceutical composition is provided, which is a substance obtained by fermentation for 10 hours under conditions kept constant at a temperature of 20-35 ° C. and a humidity of 50-65%.

The present invention comprises the first step of peeling the skin of the selected and washed beans, and then drying; A second step of mixing 30 ml of rectified water per 100 g of young barley sprouts in a mixer to obtain a young barley sprout extract; A third step of soaking the peeled beans for 6 to 12 hours to call the beans; A fourth step of pulverizing the soybeans using a grinder to obtain soymilk; A fifth step of mixing 0.01 to 1% by weight of the coagulant and 1 to 5% by weight of the young barley sprout extract of 1 to 5 months, based on 100% by weight of the soymilk obtained; Provided is a method for manufacturing a blood sugar lowering tofu, comprising a sixth step of putting the coagulated soymilk into a molding die for compression and dehydration, and then sorting and packaging the same.

Preferably, the second process comprises the steps of preparing an extract obtained by mixing 30 ml of rectified water per 100 g of barley sprout in a mixer; Fermentation was carried out for 10 hours under the conditions of keeping the temperature at 20-35 ° C. and the humidity of 50-65% by adding 0.1% by weight Aspergillus Oriza and 0.1% by weight Aspergillus element to the extract. Provided is a method for preparing blood sugar lowering tofu, further comprising.

The present invention is based on 100% by weight of soy milk obtained by grinding soy beans, 0.01 to 1% by weight of the coagulant is mixed, 1 to 5% by weight of young barley sprout extract and 1 to 5% by weight of corn beard extract Provided is a head for lowering blood sugar, which is prepared by mixing and solidifying.

Preferably, the young barley sprout extract and corn stubble extract are provided with tofu for lowering blood sugar, which is an extract obtained by mixing 100 g of barley sprout and 60 ml of rectified water per 100 g of corn stubble in a mixer.

Tofu for lowering blood sugar and a method for manufacturing the same according to the present invention has the effect of lowering blood sugar, preventing the rise of blood sugar, and increasing the secretion of insulin, and shows an excellent improvement effect on diabetes, As the astringent taste is removed through fermentation, it is easy to consume as a food, which helps to control blood sugar and prevent diabetes of diabetic patients, and thus it is very helpful for promoting national health for prevention of adult diseases. In addition, since barley sprout is contained in tofu, the prepared tofu has a blue color, which is a unique color of barley sprout, which can induce curiosity of young children, but there are no side effects of artificial colors.

EMBODIMENT OF THE INVENTION Hereinafter, this invention is demonstrated in detail with reference to drawings.

The blood glucose lowering tofu according to an embodiment of the present invention and a method for manufacturing the same are prepared by adding together the fermented extracts containing fermented young barley sprouts and corn beard extracts or young barley sprouts as an active ingredient. This removal is easy to consume, and to lower the blood sugar to the high therapeutic effect for insulin-independent diabetes and the method for producing the tofu.

The blood sugar lowering tofu according to the first embodiment of the present invention is a tofu prepared by containing an extract of young barley sprouts.

As used throughout this specification, the term 'diabetes alleviation and improvement' refers to the improvement of the symptoms caused by diabetes, and preferably refers to the act of lowering blood sugar, controlling weight, and improving lipid metabolism.

There are a variety of therapeutic drugs or medications that alleviate and improve diabetes, but therapeutic drugs or pharmaceutical agents have side effects of overdose or long-term use. However, since the young barley sprout of the present invention is a natural food, there are no side effects due to excessive or long-term use.

More specifically, young barley sprouts contain antioxidants, amino acids and minerals, as well as chlorophylls and prabonoids, various enzymes, beta-carotene and calcium, copper, folic acid, iron, magnesium, potassium, zinc, vitamin B1 and B2. , B5, B6, B12 and vitamins A, C, and E.

The antioxidants in young barley sprouts are two antioxidant enzymes (SOD, peroxidase), antioxidant vitamins A, B, C, E, polyphenols, and β-carotene. In particular, young barley sprouts are activated through the interaction of various bioactive substances and enzymes that are abundant.

Young barley grass has eight essential amino acids that are not made especially by our bodies and must be supplied from outside food. Amino acids are nutrients that produce energy, are necessary for the composition of cells and proteins, regenerate cells, and are involved in various organs of the body to maintain and improve health.

In addition, young barley sprout contains many kinds of vitamins and minerals, and various nutrients of barley sprout are easily absorbed through the digestive system.

Young barley sprouts contain a kind of polysaccharide called glucan, which reduces cholesterol, improves peripheral blood flow and is good for bronchitis, and barley eyes, like wheat eyes, prevent cancer. It is known that it contains.

According to Dr. Allan L. Goldstein of the University of Washington at George Washington, alpha-tocopherol succinate has been shown to be beneficial for many types of cancer, including leukemia, brain tumors and prostate cancer. Dr. Yoshihide of Japan said that any ingredient contained in barley sprouts is effective in treating gastric ulcers by promoting skin regeneration and promoting cell regeneration.

Example 1 Preparation of Tofu for Lowering Blood Sugar

Tofu for hypoglycemic according to the first embodiment of the present invention is mixed with 0.05% by weight of the coagulant to 100% by weight of soymilk obtained by pulverizing soybeans, 1 to 5% by weight of young barley sprouts 1 to 5 months old It is prepared by mixing and solidifying.

In more detail, the blood sugar lowering tofu according to the first embodiment of the present invention performs a preliminary preparation step after peeling the skin of the sorted and washed beans, followed by drying. In this process, the shell of the beans is peeled and dried to obtain clean soy milk.

Next, 30 ml of rectified water per 100 g of young barley sprouts are mixed in a mixer to obtain a young barley sprout extract. That is, the young barley sprout is diluted with a small amount of rectified water to obtain an extract.

In addition, the young barley sprout extract is added to the fermentation process in order to remove the inherent flaky and astringent taste. In the present invention, the barley sprout extract is preferably 0.1% by weight Aspergillus Orizae and 0.1% by weight Aspergillus for the young barley sprout extract. Inoculate the device to incubate and ferment.

In this step, the incubation temperature is preferably 25 ° C, the humidity is maintained at 53%, and the incubation time is preferably about 12 hours. During the fermentation period it is fermented by stirring for 4-6 seconds every hour at a speed of 400rpm.

Fermentation removes the inherent humiliation and astringent taste of young barley sprouts.

The stripped soybean obtained in the above process is immersed for 6 to 12 hours to call the soybeans, and the soybeans are pulverized using a grinder to obtain soymilk.

Next, 0.05 wt% of the coagulant is mixed with respect to 100 wt% of the soymilk obtained, and 1-5 wt% of the young barley sprout extract, which is 1-5 months old, is mixed.

As a coagulant, it is preferable to use a liver water, and it is preferable to use the water which drained water over a long time as possible, preferably the water drained about 3 years.

In the practice of the present invention, it is preferable that the brine is used as a coagulant by mixing with brine so that a constant liver is made to the tofu. In a preferred embodiment of the present invention, the salt water and the brine is preferably used by mixing the ratio of the weight ratio of the melt contained in the brine and the brine in a ratio of 1: 9-9: 1, even more preferably The weight ratio can be used in a mixture of 2: 8-8: 2. If the brine is too large, it takes a long time to solidify, and if the amount of brine is small, enough liver is not provided to the prepared tofu.

As a final step, the solidified soymilk is put into a mold and subjected to compression dehydration, followed by molding and packaging to complete the post-processing process.

[Experimental Example]

In order to examine the hypoglycemic effect of the head of hypoglycemic drop according to the first embodiment of the present invention, an animal experiment was first performed using a diabetic model mouse to prove the hypoglycemic effect.

As an animal experiment to investigate the hypoglycemic effect of the blood glucose-lowering tofu according to the first embodiment of the present invention, an ICR mouse was subjected to a glucose tolerance test (OGTT: Oral Glucose Tolerance Test), and the effect on diabetes was identified. Was tested using streptozotocin-induced diabetic mice.

Experimental Example 1 Measurement of Blood Glucose Dropping Level-Animal Experiment

In order to investigate the hypoglycemic effect of the hypoglycemic tofu according to the present invention, a glucose tolerance test (OGTT) was conducted using a 5-6 week old ICR mouse in SPF (Specific Pathogeus Free) state. The hypoglycemic effect of the hypoglycemic tofu of Example 1 and the control group was compared.

The dose was calculated based on the weight of 60kg adult weight was calculated to 13.4mg / kg, MOUSE DOSE was carried out by determining its 10 times 134mg / kg.

As a test method, a total of 20 experimental animals were set, divided into 2 groups of 10 animals, and fasted for 24 hours, and Experimental group 1 was rapidly dissolved in 0.85% saline solution in Example 1 and sonicated daily for 0.2 hours. Orally administered by g, Control 1 was orally administered 0.2g 0.85% saline.

After 1 hour of oral administration, 2 g / kg of D-(+)-Glucos was administered 0.2 g per 10 g of body weight in the same route. Measurement of blood glucose was measured by collecting blood from the eye every 0, 10, 30, 60, 120 minutes using a blood glucose meter manufactured by Johnson & Johnson, and the results are shown in Table 1 below.

Table 1 below shows the average value of blood glucose measured 30 minutes after oral administration of the sample.

division Experiment group 1
(Total blood pressure tofu administration group of the present invention) Control group 1 (0.85% saline administration group) Average blood sugar (mg / dl) 255.2 353.3

Experimental Example 2 Experiments on Streptozotocin-induced Diabetic Mice

Streptozotocin (STZ) is an N-nitroso derivative of D-glucosamine that was originally developed as an antibiotic. Streptozotocin reduces intracellular NAD, which is known to destroy beta cells and cause diabetes. In the present experiment, a 60 mg / kg streptozotocin was repeatedly administered to mice for 5 days to artificially induce diabetes, and then a sample was administered to compare the changes in blood sugar to monitor the effect of the hypoglycemic head of the present invention on diabetes. Observed.

The experimental animals were maintained in a clean room under the conditions of temperature 22 ° C., humidity 55 ± 5%, and illumination 12L / 12D. The test animals were divided into four groups.

Control group 2: group not administered streptozotocin

Control group 3: group intraperitoneally administered streptozotocin 60mg / kg 35 times

Control group 4: Group treated with streptozotocin 60 mg / kg and placebo 10 ml / Kg 0.85% saline solution

Experimental Group 2: Streptozotocin 60 mg / kg and placebo 10ml / Kg 0.85% saline solution and blood glucose lowering tofu of 300 mg / kg of Example 1 group

The hypoglycemic tofu was administered for 23 days from the day of administration, and blood glucose, urine glucose, and body weight were measured every 4 days.

The blood glucose measurement results for each of the control group 2, control group 3, control group 4 and experimental group 2 are shown in Table 2 below, measured only to the highest blood concentration 500mg / dl in the measurement technology. The mean blood glucose level of each group on the 8th day of drug administration was compared, and the change in the mean blood glucose level of each group of 8 days before and after drug administration was shown.

As shown in Table 2, when a blood glucose level of 300 mg / dl or more was determined as a diabetic mouse, 9 out of 10 mice tested in the control group 3 and 8 out of 10 mice in the control group 4 were diagnosed as diabetes. In comparison, in experimental group 2 treated, only 2 out of 10 cases developed.

Through the above experiments, it was found that the incidence of diabetes mellitus of STZ mice was suppressed by administering the hypoglycemic head of the present invention in the experimental group 2 to which the sample was administered.

Individual Glucose Measurements in STZ Mice Classification Days Number of experiments Average blood sugar One 2 Experiment 2 0 253 282 267 4 215 191 203 8 221 207 214 Control group 2 0 204 202 203 4 189 151 170 8 215 193 204 Control group 3 0 207 193 200 4 324 308 316 8 411 500 456 Control group 4 0 203 181 192 4 321 315 318 8 470 500 485

Example 2 Preparation of Tofu for Lowering Blood Sugar

Tofu for hypoglycemic according to a second embodiment of the present invention is mixed with 0.01 to 1% by weight of the coagulant with respect to 100% by weight of soymilk obtained by pulverizing soybeans, 1 to 5 months old young barley sprout extract It is prepared by mixing and coagulating% and 1-5 wt% corn beard extract.

At this time, the young barley sprout extract and corn whisker extract is an extract obtained by mixing 100 g of barley sprout and 60 ml of rectified water per 100 g of corn stubble in a mixer.

Experimental Example 3 Measurement of Blood Sugar Drop Level-Animal Experiment

In order to investigate the hypoglycemic effect of the hypoglycemic tofu according to the second embodiment of the present invention, a glucose tolerance test (OGTT) was performed using 5-6 weeks old ICR mice in SPF (Specific Pathogeus Free). ) To compare the blood glucose lowering effect between the blood glucose lowering head of Example 2 and the control group.

The dose was calculated based on the weight of 60kg adult weight was calculated to 13.4mg / kg, MOUSE DOSE was carried out by determining its 10 times 134mg / kg.

As a test method, a total of 20 experimental animals were set, divided into 2 groups of 10 animals, and fasted for 24 hours, and then experimental group 3 was rapidly dissolved in 0.85% saline solution in Example 2 and sonicated daily for 0.2%. Orally administered by g, Control 5 was orally administered 0.2g 0.85% saline.

After 1 hour of oral administration, 2 g / kg of D-(+)-Glucos was administered 0.2 g per 10 g of body weight in the same route. Measurement of blood glucose was measured by collecting blood from the eye every 0, 10, 30, 60, 120 minutes using a blood glucose meter manufactured by Johnson & Johnson, and the results are shown in Table 2 below.

Table 3 below shows the average value of blood glucose measured 30 minutes after oral administration of the sample.

division Experiment group 1
(Total blood pressure tofu administration group of the present invention) Control group 1 (0.85% saline administration group) Average blood sugar (mg / dl) 247.1 353.5

From the above experimental results, tofu prepared by using a young barley sprout extract or an extract mixture extracted from young barley sprout and corn whiskers according to the present invention was tested by animal experiments for insulin-dependent (type 1 diabetes) and insulin-independent (type 2 diabetes). It was found that the food composition is very useful for lowering blood sugar of the patient.

In addition, since barley sprout is contained in tofu, the prepared tofu has a blue color, which is a unique color of barley sprout, which can induce curiosity of young children, but there are no side effects of artificial colors.

On the other hand, the blood sugar lowering head and its manufacturing method according to an embodiment of the present invention is not limited to the above embodiments, but various modifications can be made without departing from the technical gist thereof.

Claims (8)

To 100% by weight of soymilk obtained by pulverizing soybeans, 0.01 to 1% by weight of a coagulant is mixed, and 1 to 5 months old and subjected to Aspergillus oryzae and Aspergillus sojae. Tofu for lowering blood sugar, which is prepared by mixing and coagulating 1 to 5% by weight of young barley sprouts fermented using. The tofu for lowering blood sugar according to claim 1, wherein the young barley sprout extract is an extract obtained by mixing 30 ml of rectified water per 100 g of barley sprout in a mixer. delete The young barley sprout extract is prepared by quenching the extract obtained by mixing 30 ml of rectified water per 100 g of barley sprout in a mixer, and preparing 0.1 wt% Aspergillus orijah and 0.1 wt% Aspergillus element. Tofu for hypoglycemic, characterized in that the substance obtained by fermentation for 10 hours under the condition of keeping constant at a temperature of 20-35 ℃, humidity of 50-65%. A first step of peeling the shells of the selected and washed beans and then drying them;
A second step of preparing an extract obtained by mixing 30 ml of rectified water per 100 g of young barley sprouts in a mixer;
A third fermentation was carried out for 10 hours under the condition of keeping constant at a temperature of 20-35 ° C. and a humidity of 50-65% by adding 0.1% by weight Aspergillus Oriza and 0.1% by weight Aspergillus element to the extract. Process;
A fourth step of soaking the peeled soybeans for 6 to 12 hours called soybeans;
A fifth step of pulverizing the soybeans using a grinder to obtain soymilk;
A sixth step of mixing 0.01 to 1% by weight of a coagulant and 1 to 5% by weight of young barley sprout extract, which is 1 to 5 months old, to 100% by weight of soymilk obtained;
A method for manufacturing a blood sugar-lowering tofu, comprising the seventh step of putting the coagulated soymilk into a molding die for compression and dehydration, and then sorting and packaging the soymilk. delete delete delete